Weleader Biomedical Co (ROCO:7713) Stock Based Compensation: NT$0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7713 Weleader Biomedical Co Ltd ROCO:7713
42 GF Score
Price NT$69.90
! 5 Warning Signs
View Full Analysis

What is Weleader Biomedical Co Stock Based Compensation?

Weleader Biomedical Co ROCO:7713 -0.57% 42 Stock Based Compensation is NT$0 Mil as of Mar. 2026. GuruFocus rates ROCO:7713 with a GF Score™ of 42/100. The stock has 5 warning signs investors should review.

Weleader Biomedical Co's Stock Based Compensation for the three months ended in Mar. 2026 was NT$0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was NT$0 Mil.

Weleader Biomedical Co Stock Based Compensation Related Terms

Weleader Biomedical Co Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Weleader Biomedical Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Weleader Biomedical Co Stock Based Compensation Chart

Weleader Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 3.65 4.23 0.18 0.00 1.61

Weleader Biomedical Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.61 0.00 0.00 0.00 0.00
ROCO:7713
42GF Score
Weleader Biomedical Co Ltd ROCO:7713
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Weleader Biomedical Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0 Mil.

What does a Stock Based Compensation of NT$0 Mil mean?
Weleader Biomedical Co (ROCO:7713) has a Stock Based Compensation of NT$0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Weleader Biomedical Co and its competitors.
Is Weleader Biomedical Co's Stock Based Compensation too high?
Weleader Biomedical Co's current Stock Based Compensation is NT$0 Mil. Overall, Weleader Biomedical Co has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's Stock Based Compensation compare to ABT and SYK?
Weleader Biomedical Co's Stock Based Compensation of NT$0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Weleader Biomedical Co and its competitors. Weleader Biomedical Co's current Stock Based Compensation is NT$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current Stock Based Compensation of NT$0 Mil. The current Stock Based Compensation is NT$0 Mil. Weleader Biomedical Co's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current Stock Based Compensation is NT$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Weleader Biomedical Co Business Description

Address No. 80, Minzu 1st Road, 19th Floor - 1 & 2, Sanmin District, Kaohsiung, TWN
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
42GF Score

Get the complete analysis for ROCO:7713

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$69.90
Price